- Q1 2024 Seres Therapeutics Inc Earnings Call TranscriptMay 08, 2024$0.7494 (-32.49%)Earnings
- Q4 2023 Seres Therapeutics Inc Earnings Call TranscriptMar 05, 2024$1.06 (-7.02%)Earnings
- Seres Therapeutics Inc at JPMorgan Healthcare Conference TranscriptJan 10, 2024
- Q3 2023 Seres Therapeutics Inc Earnings Call TranscriptNov 02, 2023$0.9324 (-35.25%)Earnings
- Seres Therapeutics Inc at Morgan Stanley Global Healthcare Conference TranscriptSep 11, 2023
- Seres Therapeutics Inc at Canaccord Genuity Growth Conference TranscriptAug 09, 2023
- Q2 2023 Seres Therapeutics Inc Earnings Call TranscriptAug 08, 2023$4.29 (-6.94%)Earnings
- Seres Therapeutics Inc at Goldman Sachs Healthcare Conference TranscriptJun 12, 2023
- Seres Therapeutics Inc at Jefferies Healthcare Conference TranscriptJun 07, 2023
- Q1 2023 Seres Therapeutics Inc Earnings Call TranscriptMay 09, 2023$5.57 (+0.18%)Earnings
- Seres Therapeutics Inc To Discuss SER-109 Approval Call TranscriptApr 27, 2023
- Q4 2022 Seres Therapeutics Inc Earnings Call TranscriptMar 07, 2023$5.4 (-1.64%)Earnings
- Seres Therapeutics Inc at JPMorgan Healthcare Conference TranscriptJan 12, 2023
- Seres Therapeutics Inc To Discuss Ser-109 Commercial Strategy Call TranscriptDec 08, 2022
- Q3 2022 Seres Therapeutics Inc Earnings Call TranscriptNov 02, 2022$8.19 (-9.50%)Earnings
- Q2 2022 Seres Therapeutics Inc Earnings Call TranscriptAug 03, 2022$4.45 (+8.54%)Earnings
- Seres Therapeutics Inc To Discuss 109 ECOSPOR IV Study Results Call TranscriptJun 07, 2022
- Q1 2022 Seres Therapeutics Inc Earnings Call TranscriptMay 04, 2022$4.72 (-2.48%)Earnings
- Q4 2021 Seres Therapeutics Inc Earnings Call TranscriptMar 01, 2022$7.4 (-7.56%)Earnings
- Seres Therapeutics Inc To Highlight Opportunities For Microbiome Therapeutics In Infection Protection Call TranscriptJan 31, 2022
- Seres Therapeutics Inc at JPMorgan Healthcare Conference (Virtual) TranscriptJan 13, 2022
- Q3 2021 Seres Therapeutics Inc Earnings Call TranscriptNov 10, 2021$8.27 (+20.38%)Earnings
- Q2 2021 Seres Therapeutics Inc Earnings Call TranscriptAug 03, 2021$6.96 (-1.00%)Earnings
- Seres Therapeutics Inc To Discuss Topline Results From The Phase 2b ECO-RESET Study Evaluating SER-287 In Patients With Mild-To-Moderate Ulcerative Colitis Call TranscriptJul 22, 2021
- Seres Therapeutics Inc SER-109 Co-Commercialization License Agreement Call TranscriptJul 01, 2021
- Seres Therapeutics Inc SER-287 Clinical Data Update Call TranscriptJun 21, 2021
- Seres Therapeutics Inc at Goldman Sachs Global Healthcare Conference (Virtual) TranscriptJun 08, 2021
- Q1 2021 Seres Therapeutics Inc Earnings Call TranscriptMay 04, 2021$21.48 (+5.55%)Earnings
- Q4 2020 Seres Therapeutics Inc Earnings Call TranscriptMar 02, 2021$19.62 (-4.85%)Earnings
- Seres Therapeutics Inc at JPMorgan Healthcare Conference (Virtual) TranscriptJan 14, 2021
- Q3 2020 Seres Therapeutics Inc Earnings Call TranscriptNov 09, 2020$33.24 (-3.90%)Earnings
- Seres Therapeutics, Inc. - Special Call TranscriptAug 10, 2020
- Seres Therapeutics Inc Annual Shareholders Meeting TranscriptJun 18, 2020
- Seres Therapeutics Inc at Goldman Sachs Global Healthcare Conference (Virtual) TranscriptJun 09, 2020
- Seres Therapeutics, Inc. - Special Call TranscriptMay 27, 2020
- Q1 2020 Seres Therapeutics Inc Earnings Call TranscriptMay 07, 2020$4.27 (+12.37%)Earnings
- Q4 2019 Seres Therapeutics Inc Earnings Call TranscriptMar 02, 2020$3.23 (+2.87%)Earnings
- Q3 2019 Seres Therapeutics Inc Earnings Call TranscriptNov 05, 2019$4.06 (+6.84%)Earnings
- Q2 2019 Seres Therapeutics Inc Earnings Call TranscriptAug 06, 2019$2.29 (-6.15%)Earnings
- Q1 2019 Seres Therapeutics Inc Earnings Call TranscriptMay 02, 2019$5.35 (-12.44%)Earnings
- Q4 2018 Seres Therapeutics Inc Earnings Call TranscriptMar 06, 2019$6.12 (-3.62%)Earnings
Seres Therapeutics Inc at Canaccord Genuity Growth Conference Transcript
Good afternoon, everybody. Thanks for joining us at the 43rd Annual Canaccord Genuity Growth Conference this afternoon. I'm John Newman. I'm one of the senior biotech analysts here at Canaccord and really excited to have I'm Eric Shaff, the CEO of Seres Therapeutics with us today. So Seres has a very unique therapy for C. difficile and are developing microbiome therapies and other areas. So Eric?
Well, good afternoon, everybody. And thank you, John, and thanks to Canaccord for having us here to present at this year's conference. We think it's a great time to connect with you with the opportunity to talk about Seres, the opportunity to talk about the microbiome, our progress in 2023, and I think as importantly, the future of the microbiome space, and importantly, the future of patients that can be helped with microbiome therapeutics.
We think that in any new modality or medical area, there can be the hope or the promise or even an aspiration
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)